/
Neurology
Alzheimer's Disease
138
Pipeline Programs↗
277
Active Trials↗
134
Companies Involved↗
Alzheimer's Disease is a highly competitive landscape with 138 programs across 134 companies. The most active players are Green Valley (Shanghai) Pharmaceuticals Co., Ltd., Roche, Eli Lilly. 20 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical32
Phase 129
Phase 257
Phase 320
Approved
No programs
Analysis
Modality Breakdown
84%
Small molecule
92 of 109 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 109 classified programs, each share of the total. Modality classified for 85% of 138 pipeline programs.
Analysis
Trial Status
1,003
clinical trials
Completed523 · 52%
Recruiting143 · 14%
Terminated119 · 12%
Unknown status65 · 6%
Not yet recruiting61 · 6%
Active, not recruiting57 · 6%
Other35 · 3%
Clinical Trials
Trial Activity
1003 trials
The International Registry for Alzheimer's Disease and Other Dementias (InRAD): An International Registry Observational Study Dedicated to Evaluating Outcomes Data in Alzheimer's Disease
Recruiting·Stichting International Registry for Alzheimer's Disease and other Dementias Foundation·N/A·NCT07213700·50,000 enrolled
Losing Specificity: the Role of the Locus Coeruleus in Age-related Distractibility
Recruiting·VVirginia Polytechnic Institute and State University·Preclinical·NCT05574634·200 enrolled
Page 1 of 67
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)